colin-and-the-presidentBig Data-Driven Effort Has Potential to Improve Health Outcomes, Save $100Bs

CAMBRIDGE, Mass. – Feb. 2, 2015 GNS Healthcare (GNS), a leading provider of analytics solutions for driving personalized interventions that improve population health, issued the following statement by its CEO and co-founder, Colin Hill. The statement follows Hill’s participation Friday at a White House briefing, where President Barack Obama revealed details of the Precision Medicine Initiative.

“GNS applauds the Precision Medicine Initiative announced on Friday by President Barack Obama. When applied across many types of healthcare interventions, precision medicine holds the potential to dramatically improve health outcomes for patients and save hundreds of billions of dollars. Payers, biopharmaceutical companies, doctors, and patients can all align around these emerging solutions that save lives and money, and improve health in a true win-win fashion. Precision medicine transcends the one-size-fits-all approach to get the right treatment to each individual patient the first time, and is transforming medicine and population health management. The result is a smarter, more impactful, and more efficient healthcare system,” says Colin Hill, GNS CEO and co-founder.

“Big data analytics and machine learning technologies are essential to fulfilling the promise of precision medicine,” continued Hill. “GNS uses these technologies to turn massive, multi-layered patient datasets into data-driven software that reliably predicts which treatments and other health interventions will work for which patients.”

“When big data analytics ‘turns the lights on’ to reveal which treatments will work for specific patients based on individual characteristics, even down to the genetic level, everything changes. Babies are saved from premature birth. Cancer patients live longer. Chronic conditions are managed closer to goal. Quality of life improves. And billions of dollars are saved by avoiding treatments that do not work for given patients and the downstream cost of not applying the right treatment the first time,” concluded Hill.

GNS has been at the forefront of this movement since 2000 and has pioneered big data-driven solutions in premature birth, multiple myeloma, Huntington’s disease, metabolic syndrome, diabetes, asthma, medication adherence, breast and colorectal cancer, multiple sclerosis, rheumatoid arthritis, childhood asthma, and others. GNS solutions bridge precision medicine and care management and are being developed and applied with world-class partners, including the Inova Translational Medicine Institute, the Dana-Farber Cancer Institute, the Multiple Myeloma Research Foundation, Massachusetts General Hospital, Aetna, Regence BlueCross BlueShield, as well as numerous biotech and pharmaceutical companies, diagnostic companies, academic clinical institutions, and government institutions.

About GNS Healthcare

GNS Healthcare provides analytic solutions that predict the impact of interventions at the individual level to optimize population health investments. Based on the MAX™ Care Management Architecture and patented REFS™ inference engine, GNS helps health plans,providers, and biopharma companies plan, implement and measure interventions that benefit individuals and drive population-level ROI. These cloud-based solutions are being deployed to improve outcomes associated with medication non-adherence, metabolic syndrome, diabetes, pre-term birth, and specialty care medications. GNS solutions focus on reducing adverse events, slowing disease progression, and improving therapeutic effectiveness through precision selection that reduces wasteful spending and maximizes impact.

GNS Healthcare
Driving Intelligent Interventions

www.gnshealthcare.com

Media Contact
Gina Veazey
703-254-6276
gveazey@gnshealthcare.com